Hepatitis C virus: Virology, diagnosis and treatment.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  World Journal of Hepatology

• Publication date

  2015-06-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.4254/wjh.v7.i10.1377PMID 26052383PMCID PMC4450201
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis C Virus

  2016cited by this paper
• Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

  2015cited by this paper
• Costs of telaprevir‐based triple therapy for hepatitis C: $189,000 per sustained virological response

  2014cited by this paper
• What are the pros and cons of the use of host-targeted agents against hepatitis C?

  2014cited by this paper
• Hepatitis C: a new direction, but an old story?

  2014cited by this paper
• Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection

  2014cited by this paper
• All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

  2014cited by this paper
• Hepatitis C treatment: an incipient therapeutic revolution.

  2014cited by this paper
• Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.

  2014cited by this paper
• ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.

  2014cited by this paper
• Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

  2014cited by this paper
• Individualization of chronic hepatitis C treatment according to the host characteristics.

  2014cited by this paper
• Hepatitis C virus associated glomerulopathies.

  2014cited by this paper
• Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

  2014cited by this paper
• Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production.

  2014cited by this paper
• New Hepatitis C Virus (HCV) Drugs and the Hope for a Cure: Concepts in Anti-HCV Drug Development

  2014cited by this paper
• HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals

  2014cited by this paper
• Performance of rapid hepatitis C virus antibody assays among high- and low-risk populations.

  2014cited by this paper
• Oral manifestations of hepatitis C virus infection.

  2014cited by this paper
• Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C

  2014cited by this paper
• Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection

  2014cited by this paper
• Antiviral therapy of hepatitis C in 2014: do we need resistance testing?

  2014cited by this paper
• Update on hepatitis C virus resistance to direct-acting antiviral agents.

  2014cited by this paper
• New Hepatitis C Therapies

  2014cited by this paper
• Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C.

  2014cited by this paper
• Mini review: current molecular methods for the detection and quantification of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1.

  2014cited by this paper
• Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays

  2014cited by this paper
• Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment.

  2014cited by this paper
• Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection.

  2014cited by this paper
• Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.

  2014cited by this paper
• Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

  2014cited by this paper
• NS 3 protease inhibitors for treatment of chronic hepatitis C : Efficacy and safety

  2014cited by this paper
• How hepatitis C virus invades hepatocytes: the mystery of viral entry.

  2014cited by this paper
• Global epidemiology and genotype distribution of the hepatitis C virus infection.

  2014cited by this paper
• NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.

  2014cited by this paper
• The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?

  2014cited by this paper
• Production and pathogenicity of hepatitis C virus core gene products.

  2014cited by this paper
• HCV RNA detection in HCV antibody-positive patients with the COBAS AmpliPrep/COBAS TaqMan HCV test, v2.0 in comparison with FDA-approved nucleic acid tests.

  2014cited by this paper
• Global Distribution and Prevalence of Hepatitis C Virus Genotypes

  2014cited by this paper
• Direct-acting antivirals trump interferon-alpha in their capacity to rescue exhausted T cells upon HCV clearance.

  2014cited by this paper
• Scotomas in molecular virology and epidemiology of hepatitis C virus.

  2013cited by this paper
• Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.

  2013cited by this paper
• Structures of hepatitis C virus nonstructural proteins required for replicase assembly and function.

  2013cited by this paper
• Ultrastructural analysis of hepatitis C virus particles

  2013cited by this paper
• Hepatitis C virus: standard-of-care treatment.

  2013cited by this paper
• Novel therapies for hepatitis C — one pill fits all?

  2013cited by this paper
• A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans

  2013cited by this paper
• The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

  2013cited by this paper
• HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial

  2013cited by this paper
• Is Sustained Virological Response a Marker of Treatment Efficacy in Patients with Chronic Hepatitis C Viral Infection with No Response or Relapse to Previous Antiviral Intervention?

  2013cited by this paper
• Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

  2013cited by this paper
• An insight into the diagnosis and pathogenesis of hepatitis C virus infection.

  2013cited by this paper
• Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis?

  2013cited by this paper
• Novel Therapeutic Approaches for Hepatitis C

  2013cited by this paper
• Virus C Hepatitis and Type 2 Diabetes: A Cohort Study in Southern Italy

  2013cited by this paper
• An inactivated hepatitis C virus vaccine on the horizon?

  2013cited by this paper
• Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden

  2013cited by this paper
• The Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 2.0, Real-Time PCR Assay Accurately Quantifies Hepatitis C Virus Genotype 4 RNA

  2013cited by this paper
• Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.

  2012cited by this paper
• Performance of the Abbott RealTime HCV Genotype II RUO Assay

  2012cited by this paper
• NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents.

  2012cited by this paper
• Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C

  2012cited by this paper
• Hepatitis C: new CDC screening recommendations.

  2012cited by this paper
• Host Genetic Variants in the Pathogenesis of Hepatitis C

  2012cited by this paper
• Virology of hepatitis C virus infection.

  2012cited by this paper
• Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid.

  2011cited by this paper
• Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity

  2011cited by this paper
• Assembly of infectious hepatitis C virus particles.

  2011cited by this paper
• Hepatitis C virus: How genetic variability affects pathobiology of disease

  2011cited by this paper
• Boceprevir for Untreated Chronic HCV Genotype 1 Infection

  2011cited by this paper
• A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

  2011cited by this paper
• Boceprevir for untreated chronic HCV genotype 1 infection.

  2011cited by this paper
• How to use virological tools for the optimal management of chronic hepatitis C

  2011cited by this paper
• A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.

  2010cited by this paper
• Ribavirin plus interferon versus interferon for chronic hepatitis C.

  2010cited by this paper
• Evaluation of in-house and commercial genotyping assays for molecular typing of hepatitis C virus in Hong Kong

  2010cited by this paper
• Ribavirin plus interferon versus interferon for chronic hepatitis C.

  2010cited by this paper
• More sensitive hepatitis C virus RNA detection: what for?

  2010cited by this paper
• Virological techniques for the diagnosis and monitoring of hepatitis B and C.

  2009cited by this paper
• Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment

  2009cited by this paper
• A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen.

  2009cited by this paper
• How to use virological tools for optimal management of chronic hepatitis C

  2009cited by this paper
• Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice

  2009cited by this paper
• Management of HCV infection: current issues and future options.

  2009cited by this paper
• The Cobas AmpliPrep‐Cobas TaqMan real‐time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples

  2009cited by this paper
• Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

  2009cited by this paper
• The Cobas AmpliPrep – Cobas TaqMan Real-Time Polymerase Chain Reaction Assay Fails To Detect Hepatitis C Virus RNA in Highly Viremic Genotype 4 Clinical Samples To the

  2009cited by this paper
• Nucleic Acids: New Tools for the Diagnostic Laboratory

  2008cited by this paper
• Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.

  2008cited by this paper
• Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0

  2008cited by this paper
• Anti-HCV IgG avidity index in acute hepatitis C.

  2007cited by this paper
• Hepatitis C virus: virology, diagnosis and management of antiviral therapy.

  2007cited by this paper
• Epidemiology of hepatitis C virus infection.

  2007cited by this paper
• Use of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5′ Untranslated Region Sequences

  2007cited by this paper
• Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay.

  2007cited by this paper
• Sequence diversity of hepatitis C virus: implications for immune control and therapy.

  2007cited by this paper
• Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office

  2006cited by this paper
• The Natural History of Hepatitis C Virus (HCV) Infection

  2006cited by this paper
• Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV Infection

  2005cited by this paper
• Genetic diversity and evolution of hepatitis C virus--15 years on.

  2004cited by this paper

• Direct-acting antiviral therapy in HCV patients: a retrospective study of the pre- and post-treatment impact in Saudi Arabia

  2026cites this paper
• Towards Accurate Identification of Anti-Hepatitis C Peptides Using Stack-AHCP

  2025cites this paper
• Trends in Mortality Caused by Hepatitis C Virus in the United States Population: A Retrospective Cross-Sectional Study Using the CDC WONDER Database

  2025cites this paper
• Efficacy and Safety of Adding Ribavirin to Sofosbuvir-Based Direct-Acting Antivirals (DAAs) in Re-Treating Non-Genotype 1 Hepatitis C—A Systematic Review and Meta-Analysis

  2025cites this paper
• Determination of the Viremia and Genotype Distribution of the Hepatitis C Virus and the Seroprevalence of HIV Co-Infection

  2025cites this paper
• In silico design of potential HCV NS5B inhibitors: a comprehensive approach combining combinatorial library generation, ensemble docking, MM-GBSA calculations, QSAR model development, and molecular dynamics

  2025cites this paper
• Sustained virological response in HCV patients receiving antiviral treatment at a teaching centre of northern India

  2025influential citation
• Analysis of the Results of Hepatitis B and C Molecular Tests in Southern Iran from 2018 to 2022, the Possibility of Hepatitis C Genotype Change in the Region

  2025cites this paper
• Interaction Between Human Microbiota, Immune System, and Hepatitis C Virus Infection: A Narrative Review

  2025cites this paper
• Efficacy of Different Combinations of Direct-Acting Antivirals Against Different Hepatitis C Virus-Infected Population Groups: An Experience in Tertiary Care Hospitals in West Bengal, India

  2025cites this paper
• Exploring the potential of some natural indoles as antiviral agents: quantum chemical analysis, inverse molecular docking, and affinity calculations

  2025cites this paper
• Comparative Analysis of Hepatitis C Virus Pathogenicity in Different Genotypes: Implications for Disease Progression and Treatment Outcomes

  2025cites this paper
• A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran

  2025cites this paper
• Secondary Analysis for Surveillance of Hepatitis C Virus Transmission from a Secondary-Level Hospital in Himachal Pradesh, India: A Brief Report

  2025cites this paper
• Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications

  2024cites this paper
• Quantum Stem Cell Therapy for Recovery of Liver Disease

  2024cites this paper
• Exploring the Impact of Different Inflammatory Cytokines on Hepatitis C Virus Infection

  2024cites this paper
• Disposable and sensitive electrochemical magneto-immunosensor for point-of-care HCV diagnostics: Targeting HCVcAg, the active viremia biomarker, in patient samples.

  2024cites this paper
• Hepatitis C Virus—Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes

  2024cites this paper
• Seroprevalence of Hepatitis C Virus and Factors Associated with It in Armenia, 2021

  2024cites this paper
• Single-molecule-binding studies of antivirals targeting the hepatitis C virus core protein

  2023cites this paper
• Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis

  2023cites this paper
• Rapid and sensitive LAMP/CRISPR-powered diagnostics to detect different hepatitis C virus genotypes using an ITO-based EG-FET biosensing platform

  2023cites this paper
• Optimizing Signal to Cut-off Values (S/Co) of Anti-HCV in Prediction of Viremia: A Retrospective Analysis with HCVRNA

  2023cites this paper
• Hepatitis C Virus Down-Regulates the Expression of Ribonucleotide Reductases to Promote Its Replication

  2023cites this paper
• An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA

  2023cites this paper
• Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes

  2023cites this paper
• Developments in Small Molecule Antiviral Drugs against Hepatitis B and C Viruses: FDA Approved Therapies and New Drugs in Clinical Trials

  2023cites this paper
• Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015–2020

  2023cites this paper
• Virus Infections in Older People.

  2023cites this paper
• Multicenter evaluation of the new Alinity s anti-HCV II assay for routine hepatitis C virus blood screening

  2023cites this paper
• Hepatitis B and C virus infections and associated factors among HIV-positive and HIV-negative tuberculosis patients in public health facilities, Northeast Ethiopia: A comparative cross-sectional study

  2023cites this paper
• ASPARTATE PLATELET RATIO INDEX AS A PREDICTOR OF SEVERITY OF FIBROSIS IN CHRONIC HEPATITS C

  2023cites this paper
• Selected feature selection methods for classifying patients with Hepatitis C

  2023cites this paper
• A novel candidate hepatitis C virus genotype 4 subtype identified by next generation sequencing full-genome characterization in a patient from Saudi Arabia

  2023cites this paper
• Stochastic two-strain epidemic model with bilinear and non-monotonic incidence rates

  2023cites this paper
• Accuracy of Rapid Serological Test versus Reference Standard Test for Hepatitis C Virus among Blood Donors

  2023cites this paper
• Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation

  2022cites this paper
• Promising Seaweeds against Human Viruses: A Review

  2022cites this paper
• Protective effect of interferon-based antiviral therapy on risk of bipolar disorder in patients with hepatitis C Virus infection: A nationwide longitudinal study

  2022cites this paper
• Chronic viral hepatitis accelerates lung function decline in smokers

  2022cites this paper
• Health Information: A Case Report of "Unknown" Hepatitis in Indonesia

  2022cites this paper
• Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors

  2022cites this paper
• A Concise Review on Hepatitis C Virus Infection-Associated Type 2 Diabetes Mellitus and Its Impact on Anti-HCV Therapy

  2022cites this paper
• Hepatitis C care cascade among patients with and without tuberculosis: findings from nationwide programs in the country of Georgia, 2015-2020

  2022cites this paper
• Targeted Proteomics for Monitoring One-Carbon Metabolism in Liver Diseases

  2022cites this paper
• Roles of microRNAs in Hepatitis C Virus Replication and Pathogenesis

  2022cites this paper
• Incidence of Diabetes in Hepatitis C Patients in Remote Areas of Pakistan: Effect of Co-Morbidity on HCV Treatment Outcomes at Selected Secondary Care Hospitals

  2022cites this paper
• Probing a Stochastic Epidemic Hepatitis C Virus Model with a Chronically Infected Treated Population

  2022influential citation
• Viral infections in Pakistan: prevalence, factors affecting spread, and recommendations for control.

  2022cites this paper
• Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches

  2022cites this paper
• 903 Protein Saver cards: the best alternative for dried blood spot storage at room temperature for HCV RNA

  2022cites this paper
• Tale of Viruses in Male Infertility.

  2022cites this paper
• Hepatitis B, C, and D Virus Infections and AFP Tumor Marker Prevalence Among the Elderly Population in Mongolia: A Nationwide Survey

  2022cites this paper
• Deciphering the significance of plasma chemokines as prognostic biomarkers in Pegylated IFN-α-2a /ribavirin-treated chronic hepatitis C genotype 4 patients.

  2022cites this paper
• Recent advances in glycyrrhizin metabolism, health benefits, clinical effects and drug delivery systems for efficacy improvement; a comprehensive review.

  2022cites this paper
• Sources, purification, immobilization and industrial applications of microbial lipases: An overview

  2022cites this paper
• Statins for the Treatment of Liver Fibrosis in Chronic Hepatitis-C Patients

  2022cites this paper
• Health state utilities of patients with hepatitis B and C and hepatitis-related conditions in Japan

  2022cites this paper
• Anti-hepatitis C virus antibody status and outcomes in serologic assays in blood donors

  2022influential citation
• Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection.

  2021cites this paper
• Noninvasive Assessment of Hepatitis C Virus Infected Patients Using Vibration-Controlled Transient Elastography

  2021cites this paper
• Hepatitis C Viral Replication Complex

  2021cites this paper
• Progress in the Development of Structure-Based Vaccines.

  2021cites this paper
• Desenho vacinal por imunoinformática contra HCV: Caracterização química e predição de epítopos de células T

  2021cites this paper
• First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients

  2021cites this paper
• Prevalence of Thyroid Dysfunction in Patients With Hepatitis C

  2021cites this paper
• Phylogenetic tree of NS5A gene of hepatitis C virus from infected Iraqi patients

  2021cites this paper
• Identification of Key Regulators of Hepatitis C Virus-Induced Hepatocellular Carcinoma by Integrating Whole-Genome and Transcriptome Sequencing Data

  2021cites this paper
• The oral microbiome of treated and untreated chronic HCV infection: A preliminary study.

  2021cites this paper
• Psychoactive Substances Taken with Mephedrone and HCV Infection

  2021cites this paper
• Hepatitis C infection and complication rates after total shoulder arthroplasty in United States veterans

  2021cites this paper
• Cellular factors involved in the hepatitis C virus life cycle

  2021cites this paper
• Discovery of Hepatitis C Virus: Nobel Prize in Physiology and Medicine 2020

  2021cites this paper
• Effectiveness of treatment with direct-acting antiviral drugs in patients with hepatitis C treated at a referral center in the Pará Sate , Brazil , from 2017 to 2019

  2021cites this paper
• Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C

  2021cites this paper
• Hepatitis C virus (HCV) diagnosis via microfluidics.

  2021cites this paper
• Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis

  2021cites this paper
• Evolution of Estimated Glomerular Filtration Rate (eGFR) in Patients with Chronic Hepatitis C Receiving Sofosbuvir-Based Direct - Acting Antivirals: A Single-Center Experience in Sub-Saharan Africa

  2021cites this paper
• RETRACTED ARTICLE: Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study

  2021cites this paper
• Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN).

  2021cites this paper
• Viral Infections and : Virus as a Case Study

  2020cites this paper
• Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection

  2020cites this paper
• MicroRNA Involvement in Signaling Pathways During Viral Infection

  2020cites this paper
• Viral Hepatitis and Iron Dysregulation: Molecular Pathways and the Role of Lactoferrin

  2020cites this paper
• High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

  2020cites this paper
• Human gene and disease associations for clinical‐genomics and precision medicine research

  2020cites this paper
• Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases

  2020cites this paper
• Prevalence, risk factors and impact of occult HCV infection on liver morbidity among haemodialysis patients: hospital-based cross-sectional study

  2020cites this paper
• The Opioid Epidemic: Associated Infections and Diagnostic Methods

  2020cites this paper
• Hepatitis B virus and hepatitis C virus co-infection among outdoor patients and indoor patients of tertiary care institute, Bathinda, Punjab, India

  2020cites this paper
• Comparison of double antigen sandwich and indirect enzyme‐linked immunosorbent assay for the diagnosis of hepatitis C virus antibodies

  2020cites this paper
• به روز رسانی ژنوتیپهای شایع ویروس هپاتیت C در اهداکنندگان خون ایران

  2020cites this paper
• Identifying genotype profile of chronic hepatitis C infection in Southwest Iran

  2020cites this paper
• Detection the Prevalence of Hepatitis C Virus among Iraqi People

  2020cites this paper
• Hepatitis C virus in Iran; transmission routes, growth in 3a genotype distribution, and lack of liver marker relation with genotypes

  2020cites this paper
• Potential for Protein Kinase Pharmacological Regulation in Flaviviridae Infections

  2020cites this paper
• Study the role of cytokines (IL-6 and TGFβ-1) and apoptosis-related proteins (PD-1 and STAT3) in the outcome of HCV infection in Wasit Province/Iraq

  2020cites this paper
• Serological prevalence of hepatitis viruses in blood samples obtained from donors in blood bank of Al-Diwaniyah Teaching Hospital: Case control study

  2020cites this paper
• Molecular Detection of Hepatitis C Virus amongst Patients in Five Selected Hospitals in Niger State, Nigeria

  2019cites this paper